Journal
TECHNOLOGY AND INNOVATION
Volume 18, Issue 1, Pages 51-61Publisher
NATL ACAD INVENTORS
DOI: 10.21300/18.1.2016.51
Keywords
Amyloid; Alzheimer's disease; Pittsburgh Compound B; Neuroimaging
Categories
Ask authors/readers for more resources
Use of biomarkers in the detection of early and preclinical Alzheimer's disease (AD) has become of central importance for the diagnosis of AD, mild cognitive impairment (MCI), and preclinical AD following publication of the NIA-Alzheimer's Association revised criteria for diagnosis across the spectrum of AD pathogenesis. The use of in vivo PET amyloid imaging agents, such as Pittsburgh Compound-B, allows early detection of AD pathological processes and subsequent neurodegeneration. Imaging with PiB provides early, or perhaps even preclinical, detection of disease and accurately distinguishes AD from dementias of other etiologies in which the diagnostic distinction is difficult to make clinically. From a research perspective, utilizing amyloid imaging agents allows us to study relationships between amyloid pathology and changes in cognition, brain structure, and function across the continuum from normal aging to MCI to AD. The present review focuses on use of PiB-PET across the spectrum of AD pathogenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available